Therapeutic cancer vaccines have undergone a resurgence in the past decade. A better
understanding of the breadth of tumour-associated antigens, the native immune response …

Cancer cells establish replicative immortality by activating a telomere-maintenance
mechanism (TMM), be it telomerase or the alternative lengthening of telomeres (ALT) …

Pancreatic ductal adenocarcinoma (PDA) is among the most immune-resistant tumor types.
Its unique genomic landscape shaped by oncogenic drivers promotes immune suppression …

This review aims to summarize the latest knowledge on factors, diagnosis, and treatment of
pancreatic cancer, and aims to promote further research on this under-studied malignant …

Pancreatic ductal adenocarcinoma (PDAC) is a highly devastating disease with poor
prognosis and rising incidence. Late detection and a particularly aggressive biology are the …

Pancreatic adenocarcinoma (PAC) is associated with extremely poor prognosis and remains
a lethal malignancy. The main cure for PAC is surgical resection. Further treatment …

Although notable progress has been made on novel cancer treatments, the overall survival
rate and therapeutic effects are still unsatisfactory for cancer patients …

The overall 5-year survival for pancreatic cancer has changed little over the past few
decades, and pancreatic cancer is predicted to be the second leading cause of cancer …

Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is
the fourth leading cause of cancer-related deaths in the world. Due to the broad …

Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second deadliest
cancer in the United States by 2025, with 5-year survival at less than 10%. In other …